Oligomerix is in discussions with several potential strategic partners, leading foundations, dementia funds and investors
and intends to collaborate in the future on its clinical development program. We welcome the opportunity for further discussions with interested parties that can reach out to us via our contact information page.
Oligomerix completed all necessary IND enabling studies and is submitting an IND to FDA during 2Q22. The company anticipates the start of first-in-human studies in 2Q22 with the goal of testing the safety and efficacy of OLX-07010 for Alzheimer’s disease and rare tauopathies.
Through our differentiated approach utilizing an oral, small molecule targeting tau-self association, OLX-07010 could complement both tau and beta-amyloid antibody treatment.